Call for Abstract
11th International Conference on Vascular Dementia, will be organized around the theme “Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health”
Vascular Dementia Congress 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vascular Dementia Congress 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Memory loss is an example. Alzheimer's is the most common type of dementia.
Semantic dementia (SD) is a progressive neurodegenerative disorder characterized by loss of semantic memory in both the verbal and non-verbal domains. However, the most common presenting symptoms are in the verbal domain (with loss of word meaning).
Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language.
Mild cognitive impairment (MCI) causes a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. A person with MCI is at an increased risk of developing Alzheimer's or another dementia.
Severe Dementia is caused by damage to brain cells. This damage interferes with the ability of brain cells to communicate with each other. When brain cells cannot communicate normally, thinking, behavior and feelings can be affected.
Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia. The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community. The stages include early dementia, Moderate dementia, Advanced dementia, Test of dementia stages, Advances in research of dementia stages.
Alzheimer's disease and other types of dementia can be a challenging journey, not only for the person diagnosed but also for their family members and loved ones. Caring for someone with Alzheimer's or dementia can seem overwhelming at times, but the more information and support you have, the better you can navigate the demanding road ahead and determine the long-term care options that are best suited to you and your loved one. There are some Alzheimer’s care preparations that are best done sooner rather than later. It may be hard to consider these questions at first, as it means thinking about a time when your loved one is already well down the road of his or her Alzheimer’s journey.
Vascular Dementia is the protection, promotion, and optimization of health and abilities, prevention of illness and injury, facilitation of healing, alleviation of suffering through the diagnosis and treatment of human response, and advocacy in the care of individuals, families, groups, communities, and populations.
The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors. Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia. Omentum in the treatment of vascular dementia. The sub tracks includes Cholinisterase inhibitors, Impact of treatment with N-Acetylcysteine, Oral redox polymer therapeutics, Snoezellen and Multi sensory stimulation, Effect of thioctic and enantiomers, Role of phospholipids, Effects of brain afobazole.
National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.
The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.